BACKGROUND: The role of multimodality therapy in stage IIIB non-small cell lung cancer (NSCLC) remains inadequately studied. Although chemoradiation is currently the mainstay of treatment, randomized trials evaluating surgical intervention are lacking, and resection is offered selectively. METHODS: Data from patients with clinical stage IIIB NSCLC (T4N2 or any N3) undergoing definitive multimodality therapy were obtained from the National Cancer Database (NCDB). Multivariable Cox regression models were fitted to evaluate variables influencing overall survival (OS). RESULTS: From 1998 to 2010, 7,459 patients with clinical stage IIIB NSCLC were treated with definitive chemoradiation (CR group), whereas 1,714 patients underwent chemotherapy, radiation, and surgical intervention in any sequence (CRS group). CRS patients were more likely to be younger and white and have slightly smaller tumors (all p < 0.01). There was no difference in Charlson Comorbidity Index (CCI) between the groups (p = 0.5). In the CRS group, 79% of patients received neoadjuvant therapy. Thirty-day surgical mortality was 3%. Factors associated with improved OS in multivariate analysis included younger age, female sex, decreased CCI, smaller tumor size, and surgical resection (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.52-0.63). Among patients treated with surgical intervention, incomplete resection was associated with decreased OS (HR, 1.52; 95% CI, 1.20-1.92). Median OS was longer in the CRS group (25.9 months versus 16.3 months; p < 0.001). Propensity matched analysis on 631 patient pairs treated with CRS versus CR confirmed these findings (median OS, 28.9 versus 17.2 months; p < 0.001). CONCLUSIONS: Surgical resection as a part of multimodality therapy may be associated with improved OS in highly selected patients with stage IIIB NSCLC. Multidisciplinary evaluation of these patients is critical.
BACKGROUND: The role of multimodality therapy in stage IIIB non-small cell lung cancer (NSCLC) remains inadequately studied. Although chemoradiation is currently the mainstay of treatment, randomized trials evaluating surgical intervention are lacking, and resection is offered selectively. METHODS: Data from patients with clinical stage IIIB NSCLC (T4N2 or any N3) undergoing definitive multimodality therapy were obtained from the National Cancer Database (NCDB). Multivariable Cox regression models were fitted to evaluate variables influencing overall survival (OS). RESULTS: From 1998 to 2010, 7,459 patients with clinical stage IIIB NSCLC were treated with definitive chemoradiation (CR group), whereas 1,714 patients underwent chemotherapy, radiation, and surgical intervention in any sequence (CRS group). CRSpatients were more likely to be younger and white and have slightly smaller tumors (all p < 0.01). There was no difference in Charlson Comorbidity Index (CCI) between the groups (p = 0.5). In the CRS group, 79% of patients received neoadjuvant therapy. Thirty-day surgical mortality was 3%. Factors associated with improved OS in multivariate analysis included younger age, female sex, decreased CCI, smaller tumor size, and surgical resection (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.52-0.63). Among patients treated with surgical intervention, incomplete resection was associated with decreased OS (HR, 1.52; 95% CI, 1.20-1.92). Median OS was longer in the CRS group (25.9 months versus 16.3 months; p < 0.001). Propensity matched analysis on 631 patient pairs treated with CRS versus CR confirmed these findings (median OS, 28.9 versus 17.2 months; p < 0.001). CONCLUSIONS: Surgical resection as a part of multimodality therapy may be associated with improved OS in highly selected patients with stage IIIB NSCLC. Multidisciplinary evaluation of these patients is critical.
Authors: M Thomas; C Rübe; M Semik; M von Eiff; L Freitag; H N Macha; W Wagner; F Klinke; H H Scheld; N Willich; W E Berdel; K Junker Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Kathy S Albain; John J Crowley; Andrew T Turrisi; David R Gandara; William B Farrar; Joseph I Clark; Kristie R Beasley; Robert B Livingston Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: V W Rusch; K S Albain; J J Crowley; T W Rice; V Lonchyna; R McKenna; R B Livingston; B R Griffin; J R Benfield Journal: J Thorac Cardiovasc Surg Date: 1993-01 Impact factor: 5.209
Authors: L Trodella; P Granone; S Valente; S Margaritora; G Macis; A Cesario; R M D'Angelillo; V Valentini; G M Corbo; V Porziella; S Ramella; G Tonini; D Galetta; M Ciresa; B Vincenzi; N Cellini Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: Nithya Ramnath; Thomas J Dilling; Loren J Harris; Anthony W Kim; Gaetane C Michaud; Alex A Balekian; Rebecca Diekemper; Frank C Detterbeck; Douglas A Arenberg Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: V W Rusch; K S Albain; J J Crowley; T W Rice; V Lonchyna; R McKenna; K Stelzer; R B Livingston Journal: Ann Thorac Surg Date: 1994-08 Impact factor: 4.330
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Vignesh Raman; Oliver K Jawitz; Chi-Fu J Yang; Soraya L Voigt; Hanghang Wang; Thomas A D'Amico; David H Harpole; Betty C Tong Journal: J Thorac Cardiovasc Surg Date: 2019-09-09 Impact factor: 5.209
Authors: Shadi Hamouri; Nasr Alrabadi; Sebawe Syaj; Hassan Abushukair; Obada Ababneh; Leen Al-Kraimeen; Majd Al-Sous; Erich Hecker Journal: Surg Today Date: 2022-01-09 Impact factor: 2.549
Authors: Elizabeth A David; Robert J Canter; Yingjia Chen; David T Cooke; Rosemary D Cress Journal: Ann Thorac Surg Date: 2016-06-09 Impact factor: 4.330
Authors: Madhusmita Behera; Conor E Steuer; Yuan Liu; Felix Fernandez; Chao Fu; Kristin A Higgins; Theresa W Gillespie; Suchita Pakkala; Rathi N Pillai; Seth Force; Chandra P Belani; Fadlo R Khuri; Walter J Curran; Suresh S Ramalingam Journal: Oncologist Date: 2020-01-14
Authors: Keshav R Paudel; Meenu Mehta; Geena Hew Suet Yin; Lee Li Yen; Vamshikrishna Malyla; Vyoma K Patel; Jithendra Panneerselvam; Thiagarajan Madheswaran; Ronan MacLoughlin; Niraj Kumar Jha; Piyush Kumar Gupta; Sachin Kumar Singh; Gaurav Gupta; Pradeep Kumar; Brian G Oliver; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua Journal: Environ Sci Pollut Res Int Date: 2022-02-16 Impact factor: 5.190